BACKGROUND AND OBJECTIVE:Mildronate, an inhibitor of carnitine-dependent metabolism, is considered to be an anti-ischemic drug. This study is designed to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke. METHODS: We performed a randomized, double-blind, multicenter clinical study of mildronate injection for treating acute cerebral infarction. 113 patients in the experimental group receivedmildronate injection, and 114 patients in the active-control group received cinepazide injection. In addition, both groups were given aspirin as a basic treatment. Modified Rankin Scale (mRS) score was performed at 2 weeks and 3 months after treatment. National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) score were performed at 2 weeks after treatment, and then vital signs and adverse events were evaluated. RESULTS: A total of 227 patients were randomized to treatment (n = 113, mildronate; n = 114, active-control). After 3 months, there was no significant difference for the primary endpoint between groups categorized in terms of mRS scores of 0-1 and 0-2 (p = 0.52 and p = 0.07, respectively). There were also no significant differences for the secondary endpoint between groups categorized in terms of NIHSS scores of >5 and >8 (p = 0.98 and p = 0.97, respectively) or BI scores of >75 and >95 (p = 0.49 and p = 0.47, respectively) at 15 days. The incidence of serious adverse events was similar between the two groups. CONCLUSION:Mildronate injection is as effective and safe as cinepazide injection in treating acute cerebral infarction.
RCT Entities:
BACKGROUND AND OBJECTIVE:Mildronate, an inhibitor of carnitine-dependent metabolism, is considered to be an anti-ischemic drug. This study is designed to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke. METHODS: We performed a randomized, double-blind, multicenter clinical study of mildronate injection for treating acute cerebral infarction. 113 patients in the experimental group received mildronate injection, and 114 patients in the active-control group received cinepazide injection. In addition, both groups were given aspirin as a basic treatment. Modified Rankin Scale (mRS) score was performed at 2 weeks and 3 months after treatment. National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) score were performed at 2 weeks after treatment, and then vital signs and adverse events were evaluated. RESULTS: A total of 227 patients were randomized to treatment (n = 113, mildronate; n = 114, active-control). After 3 months, there was no significant difference for the primary endpoint between groups categorized in terms of mRS scores of 0-1 and 0-2 (p = 0.52 and p = 0.07, respectively). There were also no significant differences for the secondary endpoint between groups categorized in terms of NIHSS scores of >5 and >8 (p = 0.98 and p = 0.97, respectively) or BI scores of >75 and >95 (p = 0.49 and p = 0.47, respectively) at 15 days. The incidence of serious adverse events was similar between the two groups. CONCLUSION:Mildronate injection is as effective and safe as cinepazide injection in treating acute cerebral infarction.
Authors: Anders Bach; Bettina H Clausen; Magda Møller; Bente Vestergaard; Celestine N Chi; Adam Round; Pernille L Sørensen; Klaus B Nissen; Jette S Kastrup; Michael Gajhede; Per Jemth; Anders S Kristensen; Patrik Lundström; Kate L Lambertsen; Kristian Strømgaard Journal: Proc Natl Acad Sci U S A Date: 2012-02-17 Impact factor: 11.205
Authors: Chikara Otsubo; Sivakama Bharathi; Radha Uppala; Olga R Ilkayeva; Dongning Wang; Kevin McHugh; Ye Zou; Jieru Wang; John F Alcorn; Yi Y Zuo; Matthew D Hirschey; Eric S Goetzman Journal: J Biol Chem Date: 2015-08-03 Impact factor: 5.157
Authors: Chengheng Liao; Yang Zhang; Cheng Fan; Laura E Herring; Juan Liu; Jason W Locasale; Mamoru Takada; Jin Zhou; Giada Zurlo; Lianxin Hu; Jeremy M Simon; Travis S Ptacek; Victor G Andrianov; Einars Loza; Yan Peng; Huanghe Yang; Charles M Perou; Qing Zhang Journal: Cancer Discov Date: 2020-07-20 Impact factor: 38.272